{"filing":{"accession_number":"0001140361-26-034857","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"ef20080970_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126034857/ef20080970_8k.htm"},"events":[{"id":30396,"run_id":27858,"accession_number":"0001140361-26-034857","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 discloses the results of a special shareholder meeting held on August 28, 2026, where Crinetics shareholders voted on three proposals, most critically the merger with Vertex Pharmaceuticals. Proposal No. 1 (the Merger Proposal) was approved with 79,240,098 votes in favor versus 13,618 against, satisfying the final outstanding condition to close the merger. The filing explicitly states the approval \"satisfies the final outstanding condition to the closing of the Merger\" and anticipates closing on or about September 1, 2026, making this a material M\u0026A milestone disclosed through shareholder vote results.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32975,"accession_number":"0001140361-26-034857","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of a special shareholder meeting held on August 28, 2026, where Crinetics shareholders voted on three proposals, most critically the merger with Vertex Pharmaceuticals. Proposal No. 1 (the Merger Proposal) was approved with 79,240,098 votes in favor versus 13,618 against, satisfying the final outstanding condition to close the merger. The filing explicitly states the approval \"satisfies the final outstanding condition to the closing of the Merger\" and anticipates closing on or about September 1, 2026, making this a material M\u0026A milestone disclosed through shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:04:01.565294+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32975,"accession_number":"0001140361-26-034857","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of a special shareholder meeting held on August 28, 2026, where Crinetics shareholders voted on three proposals, most critically the merger with Vertex Pharmaceuticals. Proposal No. 1 (the Merger Proposal) was approved with 79,240,098 votes in favor versus 13,618 against, satisfying the final outstanding condition to close the merger. The filing explicitly states the approval \"satisfies the final outstanding condition to the closing of the Merger\" and anticipates closing on or about September 1, 2026, making this a material M\u0026A milestone disclosed through shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:04:01.565294+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-28"}]}